Forecast Report - Epilepsy Therapeutics Market Size, Share, Growth & Worldwide, 2019: Radiant Insights, Inc
GBI Research, the leading business intelligence provider, has released its latest research, "Epilepsy Therapeutics in Asia Pacific Markets to 2019 - Treatment Options Enhanced As Novel Next Generation AEDs Show Improved Safety and Tolerability", which provides in-depth analysis of epilepsy market within the Asia-Pacific (APAC) market covering the four countries of Australia, China, India and Japan. The report provides an estimation of market size for 2012, along with market forecast until 2019. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of the pipeline, and deal analysis. Read Complete Report with TOC @ http://www.radiantinsights.com/research/epilepsy-therapeutics-in-asia-pacific-markets-to-2019-treatment-options-enhanced-as-novel-next-generation-aeds-show-improved-safety-and-tolerability The value of the epilepsy market in the APAC region amounted to an estimated $1.1 billion in 2012 and is expected to register a Compound Annual Growth Rate (CAGR) of 4.7% to reach $1.5 billion by 2019. The key drivers for growth in the APAC market include: high prevalence in China and India, increased market penetration due to improved market access in China and the expected approvals of drugs with novel mechanisms of action which could expand the therapeutic Scope. Conversely, the growth of the market in APAC region could face the restricting influence of prescribing patterns that give preference to older generation drugs and also due to generic competition as a result of key patent expiries. Scope The report analyzes treatment usage patterns, market characterization, pipeline analysis and key licensing and co-development deals in anti-epileptics in the four APAC markets of Australia, China, India and Japan. The report includes - - A brief introduction to epilepsy, including disease pathogenesis, risk factors, diagnosis and treatment options - In-depth analysis of major marketed products covering product performance, product life-cycle and a heat map depicting comparative analysis of safety and efficacy parameters - A comprehensive review of the epilepsy pipeline which includes individual analysis of promising late-stage pipeline drugs that are likely to enter the market during the forecast period. The pipeline is analyzed on the basis of Phase distribution, molecule type and molecular target.
GBI Research, the leading business intelligence provider, has released its latest research, "Epilepsy Therapeutics in Asia Pacific Markets to 2019 - Treatment Options Enhanced As Novel Next Generation AEDs Show Improved Safety and Tolerability", which provides in-depth analysis of epilepsy market within the Asia-Pacific (APAC) market covering the four countries of Australia, China, India and Japan. The report provides an estimation of market size for 2012, along with market forecast until 2019. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of the pipeline, and deal analysis.
Read Complete Report with TOC @ http://www.radiantinsights.com/research/epilepsy-therapeutics-in-asia-pacific-markets-to-2019-treatment-options-enhanced-as-novel-next-generation-aeds-show-improved-safety-and-tolerability
The value of the epilepsy market in the APAC region amounted to an estimated $1.1 billion in 2012 and is expected to register a Compound Annual Growth Rate (CAGR) of 4.7% to reach $1.5 billion by 2019. The key drivers for growth in the APAC market include: high prevalence in China and India, increased market penetration due to improved market access in China and the expected approvals of drugs with novel mechanisms of action which could expand the therapeutic Scope. Conversely, the growth of the market in APAC region could face the restricting influence of prescribing patterns that give preference to older generation drugs and also due to generic competition as a result of key patent expiries.
Scope
The report analyzes treatment usage patterns, market characterization, pipeline analysis and key licensing and co-development deals in anti-epileptics in the four APAC markets of Australia, China, India and Japan. The report includes -
- A brief introduction to epilepsy, including disease pathogenesis, risk factors, diagnosis and treatment options
- In-depth analysis of major marketed products covering product performance, product life-cycle and a heat map depicting comparative analysis of safety and efficacy parameters
- A comprehensive review of the epilepsy pipeline which includes individual analysis of promising late-stage pipeline drugs that are likely to enter the market during the forecast period. The pipeline is analyzed on the basis of Phase distribution, molecule type and molecular target.
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
2.11 Non-pharmacological Management 15<br />
2.11.1 Lobectomy and Lesionectomy 15<br />
2.11.2 Ketogenic Diet and Modified Atkins Diet 15<br />
2.11.3 Vagus Nerve Stimulation 16<br />
3 <strong>Epilepsy</strong> Therapeutic Landscape 17<br />
3.1 Overview 17<br />
3.2 Lyrica (pregabalin) 17<br />
3.3 Lamictal (lamotrigine) 18<br />
3.4 Keppra (levetiracetam) 19<br />
3.5 Zonegran (zonisamide) 21<br />
<strong>Epilepsy</strong> <strong>Therapeutics</strong> in Major Developed <strong>Market</strong>s to <strong>2019</strong> -<br />
http://www.radiantinsights.com/research/epilepsy-therapeutics-in-major-developed-markets-to-<br />
<strong>2019</strong>-new-aeds-with-novel-mechanisms-of-action-signal-a-shift-in-treatment-patterns<br />
3.6 Vimpat (lacosamide) 22<br />
3.7 Aptiom/Zebinix (eslicarbazepine acetate) 24<br />
3.8 Fycompa (perampanel) 24<br />
3.9 Trobalt/Potiga (ezogabine/retigabine) 25<br />
3.10 Banzel/Inovelon (rufinamide) 26<br />
3.11 Comparative Efficacy and Safety of <strong>Market</strong>ed Products 26<br />
4 Pipeline for <strong>Epilepsy</strong> <strong>Therapeutics</strong> 29<br />
4.1 Overall Pipeline 29<br />
4.2 Pipeline by Mechanism of Action 31<br />
4.3 Clinical Trials 32<br />
4.3.1 Failure Rate 32<br />
4.3.2 Patient Enrolment and Clinical Trial <strong>Size</strong> 34<br />
4.3.3 Clinical Trial Duration 36<br />
4.4 Promising Pipeline Candidates 38
Change language